Log in or create an account for full access to this data.
Create a free account or log in to use this tool.
Create a free account or log in to explore DrugBank data.
Talampanel is a substance that is being studied in the treatment of brain tumors and other brain disorders, such as epilepsy and Parkinson disease. It is a type of AMPA...
- Mechanism
- Curator reviewed
Talampanel is a potent noncompetitive and selective antagonist of the glutamine AMPA receptors. Studies in primates have shown that the administration of talampanel to parkinsonian monkeys significantly decreased levodopa-induced dyskinesias by 40%. When given alone, talampanel did not modify the severity of parkinsonian symptoms. However, in combination with levodopa, talampanel potentiated the antiparkinsonian action of levodopa by increasing motor activity.
- Primary indication
- For the treatment of epilepsy.Curator reviewed
- Formula / weight
- C19H19N3O3 · 337.3725 g/mol (avg)
- Code names
- GYKI 53405 · GYKI-53773 · LY-300164
Resolves to
JACAAXNEHGBPOQ-LLVKDONJSA-NSMILESC[C@@H]1CC2=CC3=C(OCO3)C=C2C(=NN1C(C)=O)C1=CC=C(N)C=C1What you can answer from here — as of June 15, 2026
Which drugs share a target with Talampanel, and which of those have an active Phase 3 trial?